Phathom Pharmaceuticals Gets FDA Approval for Voquezna Treatment
By Sabela Ojea
Phathom Pharmaceuticals said the U.S. Food and Drug Administration approved Voquezna to treat a type of esophagus inflammation.
The commercial-stage biopharmaceutical company said the FDA approved the novel potassium-competitive acid blocker as a new treatment for adults dealing with erosive esophagitis.
The approval is based on positive results from the phase 3 Phalcon-EE study, which enrolled over 1,000 patients in the U.S. and Europe.
Voqezna is expected to be available in the U.S. in December, the company said.
The FDA approval entitles Phathom Pharmaceuticals to receive a $175 million payment, which will fund the commercial launch.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
November 01, 2023 17:35 ET (21:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst